Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 609,914 | 994,959 | 1,000,899 | 285,908 | 652,664 |
| Depreciation Amortization | 1,230,208 | 5,023,214 | 3,680,554 | 2,443,959 | 1,251,957 |
| Accounts receivable | -305,562 | 104,218 | -399,792 | -504,259 | -659,723 |
| Accounts payable and accrued liabilities | -239,712 | -68,276 | 139,992 | -342,785 | -252,989 |
| Other Working Capital | -1,215,865 | -1,818,557 | -2,144,577 | -1,030,563 | -1,595,685 |
| Other Operating Activity | 1,010,963 | 707,215 | 699,666 | 1,157,745 | 1,278,296 |
| Operating Cash Flow | $1,089,946 | $4,942,773 | $2,976,741 | $2,010,005 | $674,520 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -367,565 | -1,151,017 | -831,504 | -520,722 | -335,406 |
| Net Acquisitions | 18,822 | 137,717 | 2,482 | 2,519 | 2,716 |
| Purchase Of Investment | -83,072 | -46,685 | -32,123 | -15,622 | -4,920 |
| Sale Of Investment | 34,029 | 55,345 | 7,405 | 4,354 | 3,964 |
| Purchase Sale Intangibles | -514,285 | -2,106,639 | -1,941,536 | -1,762,784 | -1,629,944 |
| Other Investing Activity | -605,049 | -2,196,008 | -1,882,430 | -1,727,581 | -1,612,023 |
| Investing Cash Flow | $-1,002,835 | $-3,200,648 | $-2,736,170 | $-2,257,052 | $-1,945,669 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 3,248,883 | 690,000 | 680,000 | 690,000 | 730,000 |
| Debt Repayment | -320,698 | -2,214,217 | -2,181,556 | -1,698,028 | -730,642 |
| Common Stock Repurchased | -12,045 | -16,049 | -15,817 | -16,049 | -16,980 |
| Dividend Paid | -883,904 | -1,981,597 | -1,890,822 | -964,696 | -954,446 |
| Other Financing Activity | -7,399 | 1,076,393 | 1,394,083 | 619,585 | 550,289 |
| Financing Cash Flow | $2,024,838 | $-2,445,470 | $-2,014,112 | $-1,369,188 | $-421,779 |
| Exchange Rate Effect | 110,208 | 180,808 | 106,379 | 129,437 | 107,741 |
| Beginning Cash Position | 2,929,920 | 3,681,357 | 3,628,004 | 3,681,357 | 3,894,769 |
| End Cash Position | 5,147,341 | 3,158,820 | 1,960,841 | 2,194,552 | 2,309,574 |
| Net Cash Flow | $2,217,421 | $-522,537 | $-1,667,163 | $-1,486,805 | $-1,585,195 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,089,946 | 4,942,773 | 2,976,741 | 2,010,005 | 674,520 |
| Capital Expenditure | -367,622 | -1,210,398 | -890,011 | -578,248 | -335,486 |
| Free Cash Flow | 722,324 | 3,732,375 | 2,086,730 | 1,431,757 | 339,034 |